705945-68-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-TCFP-RH is used as a catalyst in the asymmetric reduction of amines, ketones, and unsaturated acids for the production of pharmaceutical compounds. Its high selectivity and efficiency enable the synthesis of enantiomerically pure compounds, which are essential for the development of effective and safe drugs.
Used in Chemical Synthesis:
(S)-TCFP-RH is used as a hydrogenation catalyst in the preparation of diastereomers of trifluorovaline, a key intermediate in the synthesis of various pharmaceutical compounds. Its ability to selectively catalyze this transformation allows for the efficient production of the desired diastereomers with minimal side products.
Used in Organic Chemistry Research:
(S)-TCFP-RH is used as a catalyst in the olefin asymmetric hydrogenation, a reaction that is crucial in the synthesis of chiral compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science. Its high selectivity and reactivity make it an ideal choice for researchers working on the development of new chiral molecules and materials.

Upstream product

• 35138-22-8 bis(1,5-cyclooctadiene)rhodium(I) tetrafluoroborate 
• 705945-65-9 P(CH₃)C(CH₃)3CH₂P(C(CH₃)3)2 
• 705945-65-9 P(CH₃)C(CH₃)3CH₂P(C(CH₃)3)2 
• 705945-65-9 (R)-tert-butylmethylphosphino-di-tert-butylphosphinomethane 
• 1552-12-1 1,5-cis,cis-cyclooctadiene 

Downstream Products

• 1008533-32-1 (Rh(((CH₃)3C)2PCH₂P(CH₃)(C(CH₃)3))(CH₃CONHC(COOCH₃)CHC₆H₅))⁽¹⁺⁾ 
• 1008533-33-2 (Rh(((CH₃)3C)2PCH₂P(CH₃)(C(CH₃)3))(CH₃CONHC(COOCH₃)CHC₆H₅))⁽¹⁺⁾ 

Relevant academic research and scientific papers

PROCESS FOR PREPARING CATIONIC RHODIUM COMPLEXES

A process is described for the synthesis of a cationic [rhodium diolefin phosphorus ligand] complex comprising the steps of: (a) reacting a rhodium-diolefin-1,3-diketonate and an acid in a ketone solvent, (b) adding a stabilising olefin to form a stabilised cationic rhodium compound, and (c) mixing a phosphorus ligand with the solution of the stabilised cationic rhodium compound to form a solution of the cationic [rhodium diolefin phosphorus ligand] complex. The solution may be used directly or the complex recovered. In one embodiment, the solution may be combined with a co-solvent and the ketone removed to give a new catalyst solution, from which the complex may be recovered.

C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin

Materials and methods for preparing (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid and structurally related compounds via enantioselective hydrogenation of prochiral olefins are disclosed. The methods employ novel chiral catalysts, which include C1-symmetric bisphosphine ligands bound to transition metals.

Highly Selective Asymmetric Hydrogenation Using a Three Hindered Quadrant Bisphosphine Rhodium Catalyst

A concise synthesis of both enantiomers of ligand 2 and rhodium complex 5 is presented. The crux of the synthesis is a chiral HPLC separation of the enantiomers of 4. Rhodium complex 5 possesses three hindered quadrants in the steric environment within which a substrate binds. Evidence is presented that this configuration leads to high enantioselectivity (>99% ee) for rhodium-catalyzed asymmetric hydrogenation of α-acetamido dehydroamino acids, 6a-e. High enantioselectivities are also reported for the hydrogenation of a substrate precursor, 8, of pharmaceutical candidate, pregabalin. Advantages for large-scale hydrogenation of 8 using catalyst 5a vs Rh-Me-DuPhos are discussed. Copyright